athenahealth, Inc. (NASDAQ:ATHN)‘s stock had its “positive” rating reissued by investment analysts at Leerink Swann in a research report issued on Monday, The Fly reports. They presently have a $155.00 target price on the health services provider’s stock, up from their prior target price of $140.00. Leerink Swann’s price objective would suggest a potential downside of 0.60% from the company’s previous close.

ATHN has been the subject of several other research reports. UBS AG reaffirmed a “buy” rating and issued a $152.00 target price (up previously from $123.00) on shares of athenahealth in a research note on Wednesday, May 31st. Citigroup Inc. reaffirmed a “buy” rating and issued a $163.00 target price (up previously from $128.00) on shares of athenahealth in a research note on Monday, June 5th. Piper Jaffray Companies reaffirmed a “buy” rating and issued a $152.00 target price on shares of athenahealth in a research note on Friday, July 14th. Oppenheimer Holdings, Inc. upped their target price on athenahealth from $154.00 to $184.00 and gave the stock an “outperform” rating in a research note on Friday. Finally, Wells Fargo & Company reaffirmed an “outperform” rating and issued a $190.00 target price (up previously from $130.00) on shares of athenahealth in a research note on Saturday. Two analysts have rated the stock with a sell rating, eleven have assigned a hold rating and thirteen have assigned a buy rating to the company’s stock. athenahealth has a consensus rating of “Hold” and a consensus price target of $147.24.

athenahealth (ATHN) opened at 155.93 on Monday. athenahealth has a one year low of $90.11 and a one year high of $158.66. The company has a market cap of $6.23 billion, a price-to-earnings ratio of 197.88 and a beta of 1.79. The company has a 50-day moving average of $141.51 and a 200-day moving average of $122.62.

athenahealth (NASDAQ:ATHN) last issued its earnings results on Thursday, July 20th. The health services provider reported $0.51 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.39 by $0.12. The business had revenue of $301.10 million during the quarter, compared to analyst estimates of $298.68 million. athenahealth had a return on equity of 6.91% and a net margin of 2.80%. athenahealth’s revenue for the quarter was up 15.0% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.34 earnings per share. Equities research analysts expect that athenahealth will post $1.89 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This piece was posted by American Banking News and is owned by of American Banking News. If you are reading this piece on another website, it was copied illegally and reposted in violation of United States & international copyright and trademark legislation. The original version of this piece can be read at https://www.americanbankingnews.com/2017/07/24/athenahealth-inc-athn-receives-positive-rating-from-leerink-swann.html.

In other athenahealth news, SVP Jonathan D. Porter sold 300 shares of the stock in a transaction on Monday, May 15th. The stock was sold at an average price of $109.48, for a total value of $32,844.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Brandon H. Hull sold 800 shares of the stock in a transaction on Monday, July 3rd. The stock was sold at an average price of $140.81, for a total value of $112,648.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 26,105 shares of company stock valued at $3,394,859. 3.20% of the stock is owned by corporate insiders.

Institutional investors have recently bought and sold shares of the company. BlackRock Inc. increased its position in athenahealth by 30,642.6% in the first quarter. BlackRock Inc. now owns 1,599,847 shares of the health services provider’s stock worth $180,286,000 after buying an additional 1,594,643 shares during the period. Morgan Stanley increased its position in athenahealth by 9.7% in the first quarter. Morgan Stanley now owns 4,514,305 shares of the health services provider’s stock worth $508,717,000 after buying an additional 397,837 shares during the period. Clearbridge Investments LLC increased its position in athenahealth by 61.8% in the first quarter. Clearbridge Investments LLC now owns 908,505 shares of the health services provider’s stock worth $102,379,000 after buying an additional 347,133 shares during the period. Credit Suisse AG increased its position in athenahealth by 404.5% in the first quarter. Credit Suisse AG now owns 300,420 shares of the health services provider’s stock worth $33,854,000 after buying an additional 240,876 shares during the period. Finally, Norges Bank purchased a new position in athenahealth during the fourth quarter worth about $20,750,000.

About athenahealth

athenahealth, Inc provides network-based medical record, revenue cycle, patient engagement, care coordination and population health services. The Company also offers Epocrates and other point-of-care mobile applications. The Company delivers majority of its service offerings through a single instance of cloud-based software, athenaNet.

The Fly

Analyst Recommendations for athenahealth (NASDAQ:ATHN)

Receive News & Ratings for athenahealth Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for athenahealth Inc. and related companies with MarketBeat.com's FREE daily email newsletter.